summary
Introduced
04/29/2019
04/29/2019
In Committee
04/30/2019
04/30/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
A BILL To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market. HR 2375 RH 1
AI Summary
This bill aims to prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of generic drugs, biosimilar biological products, or interchangeable biological products into the market. It would enhance competition in the pharmaceutical market by stopping anti-competitive agreements between brand name and generic drug manufacturers that limit, delay, or prevent competition from generic and biosimilar products. The bill would treat such agreements as unfair methods of competition under the Federal Trade Commission Act and allow the FTC to enforce its provisions and impose penalties. It would also require certain notifications and certifications related to these types of agreements.
Committee Categories
Health and Social Services, Justice
Sponsors (5)
Last Action
Placed on the Union Calendar, Calendar No. 576. (on 12/24/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...